Islet Cell Replacement Therapy for Insulin-Dependent Diabetes
- PMID: 29369575
- Bookshelf ID: NBK476438
Islet Cell Replacement Therapy for Insulin-Dependent Diabetes
Excerpt
ViaCyte’s PEC-Direct and PEC-Encap (VC-01) products offer a potential “functional cure” for patients with type 1 diabetes and insulin-dependent type 2 diabetes.
Using human pancreatic progenitor cells (PEC-01) created in the lab, both the PEC-Direct and the PEC-Encap products are implanted into patients, where they mature into functional pancreatic islet tissue that includes glucose-responsive insulin-producing beta cells.
The PEC-Encap product offers the additional benefit of an encapsulation device designed to protect the cells from the immune system.
The current evidence is limited to phase I and II human trials evaluating the safety of the PEC-Encap product and pre-clinical study of the PEC-Direct product.
There are insufficient data about efficacy in humans, adverse effects, and the length of time the product can remain safely implanted and functional.
The future cost of ViaCyte’s products is unknown.
Copyright © CADTH 2017. You are permitted to reproduce this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH.
Sections
Similar articles
-
Concise Review: Manufacturing of Pancreatic Endoderm Cells for Clinical Trials in Type 1 Diabetes.Stem Cells Transl Med. 2015 Aug;4(8):927-31. doi: 10.5966/sctm.2015-0058. Epub 2015 Jun 10. Stem Cells Transl Med. 2015. PMID: 26062982 Free PMC article. Review.
-
Insulin-Producing Endocrine Cells Differentiated In Vitro From Human Embryonic Stem Cells Function in Macroencapsulation Devices In Vivo.Stem Cells Transl Med. 2015 Oct;4(10):1214-22. doi: 10.5966/sctm.2015-0079. Epub 2015 Aug 24. Stem Cells Transl Med. 2015. PMID: 26304037 Free PMC article.
-
Insulin expression and C-peptide in type 1 diabetes subjects implanted with stem cell-derived pancreatic endoderm cells in an encapsulation device.Cell Rep Med. 2021 Dec 2;2(12):100466. doi: 10.1016/j.xcrm.2021.100466. eCollection 2021 Dec 21. Cell Rep Med. 2021. PMID: 35028608 Free PMC article. Clinical Trial.
-
I. Progress Towards a Stem Cell Based Therapy for Diabetes.J Stem Cells Regen Med. 2021 Dec 30;17(2):61. doi: 10.46582/jsrm.1702010. eCollection 2021. J Stem Cells Regen Med. 2021. PMID: 35250203 Free PMC article.
-
Concise Review: Markers for Assessing Human Stem Cell-Derived Implants as β-Cell Replacement in Type 1 Diabetes.Stem Cells Transl Med. 2016 Oct;5(10):1338-1344. doi: 10.5966/sctm.2015-0187. Epub 2016 Jul 5. Stem Cells Transl Med. 2016. PMID: 27381993 Free PMC article. Review.
References
-
- Cell replacement therapy [Internet] Hollywood (FL): Diabetes Research Institute Foundation; 2016. [cited 2017 Feb 27]. Available from: https://www.diabetesresearch.org/cell-replacement-therapy.
-
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Goldenberg R, Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. 2013 Apr;37 Suppl 1:S8–11. - PubMed
-
- ViaCyte [Internet] San Diego (CA): ViaCyte; 2017. [cited 2017 Feb 14]. Available from: http://viacyte.com/
-
- The Edmonton protocol [Internet] Edmonton: University of Alberta, Alberta Diabetes Institute; 2017. [cited 2017 Feb 14]. Available from: http://adi.ualberta.ca/en/ResearchAreas/IsletCellBiologyandPhysiology/On....
-
- Desai T, Shea LD. Advances in islet encapsulation technologies. Nat Rev Drug Discov. 2016 Dec 23; - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous